Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: Injection Rabeprazole 20 mg: IV Rabeprazole 20 mg injected along with preanesthetic medication
Control Intervention1: None: Patients will receive only Pre-anaesthetic medication as per
Sponsors
D Y Patil University School of Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who will be undergoing elective surgery under general anesthesia 2. Patients who will require endotracheal intubation. 3. American Society of Anesthesiologists (ASA) physical status I (a normal healthy patient) and class-II (a patient with mild systemic disease). 4. Female patients must have a negative urine pregnancy test at screening. 5. Patient capable of understanding, providing written informed consent and follow study related procedures.
Exclusion criteria
Exclusion criteria: 1. Patient with known hypersensitivity and contraindication to Rabeprazole, or any study treatment. 2. Obese patients who will be >20% heavier than their ideal body weight &/or body mass index (BMI) more than 40 kg/m2. 3. Patients taking medication known to affect gastric fluid composition or gastric emptying. 4. Patients with any upper gastrointestinal disorders. 5. Patient receiving medications known to affect the secretory and/or motor functions of the stomach. 6. Mallampati class IV (soft palate not visible at all) and/or mouth opening less than 5 cm and/or thyromental distance less than 6.5 cm. 7. Patients with contraindication to orogastric/nasogastric tube placement. 8. Patients with history of difficult intubation, intestinal obstruction, parturients, diabetes mellitus. 9. IV &/oral administration of PPI within 24 hour before randomization. 10. Patient with suspicion of gastric malignancy. 11. Patient with Zollinger-Ellison syndrome. 12. Patient taking a drug known to interact with PPIs (phenytoin, clarithromycin, itraconazole, ketoconazole, warfarin, cyclosporine and other vitamin K antagonists, cisapride, atazanavir, or ritonavir) within 24 hour before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric pH (fluid aspirate from nasogastric tube)Timepoint: 90-120 minutes after injection | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume of gastric contents (fluid aspirate from nasogastric tube)Timepoint: 90-120 minutes after injection | — |
Countries
India
Contacts
Public ContactDeepakkumar Langade
D Y Patil University School of Medicine and Hospital
Outcome results
None listed